thrm-8k_20200804.htm
false GENTHERM Inc 0000903129 0000903129 2020-08-04 2020-08-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 4, 2020

 

GENTHERM INCORPORATED

(Exact name of registrant as specified in its charter)

 

 

 

Michigan

 

0-21810

 

95-4318554

 

 

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

 

21680 Haggerty Road, Northville, MI

48167

 

 

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (248) 504-0500

Former name or former address, if changed since last report: N/A

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common Stock, no par value

 

THRM

 

Nasdaq

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 


Item 2.02

Results of Operations and Financial Condition.

On August 4, 2020, Gentherm Incorporated (the “Company”) publicly announced its financial results for the second quarter of 2020. A copy of the Company’s news release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. On August 4, 2020 at 8:00 a.m. Eastern Time, the Company will host a conference call to discuss the second quarter of 2020 financial results. A copy of the supplemental materials that will be used during the conference call is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 2.02 and the attached exhibits 99.1 and 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly stated by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

 

Exhibit 99.1

  

Company news release dated August 4, 2020 concerning financial results

 

 

 

Exhibit 99.2

  

Supplemental materials dated August 4, 2020

 

 

 

Exhibit 104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

GENTHERM INCORPORATED

 

 

 

 

By:

 

/s/ Wayne Kauffman

 

 

 

Wayne Kauffman

 

 

 

Vice President and General Counsel

Date:  August 4, 2020

 

 

 

 

thrm-ex991_70.htm

 

Exhibit 99.1

Gentherm Reports 2020 Second Quarter Results

 

Reduced Operating Expenses by 30% from the Prior-year Period

Strong Cash Flow Generation in the First Half of 2020 Despite Unprecedented Market Challenges

Total Liquidity of $369 Million at Quarter End

 

NORTHVILLE, Michigan, August 4, 2020 /Global Newswire/ - Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management technologies, today announced its financial results for the second quarter ended June 30, 2020.

Second Quarter Highlights

 

Product revenues of $136.1 million decreased 44.1% from $243.3 million in the 2019 second quarter

 

Excluding the impact of foreign currency translation and divested assets, product revenues decreased 42.3% year over year

 

GAAP diluted loss per share was $0.32 compared to diluted earnings per share of $0.08 for the prior-year period

 

Adjusted loss per share (see table herein) was $0.30. Adjusted earnings per share in the prior-year period was $0.47

 

Secured automotive new business awards totaling $300 million

 

Phil Eyler, Gentherm's President and CEO, said “I am proud of the team for their strong execution in the second quarter despite the unprecedented uncertainties created by the worldwide COVID-19 pandemic. While the Company’s revenue performance reflects the challenges in the underlying markets, our ongoing disciplined approach to managing expenses allowed us to reduce operating expense by 30% from a year ago.  In Medical, we delivered double-digit revenue growth both year over year and sequentially. Importantly, we generated a 24% increase in cash flow from operations in the first half of 2020 versus the prior-year period.

 

“While the COVID-19 pandemic will continue to create challenges and uncertainties in the near term, the momentum we are seeing in new awards, winning the coveted General Motors Supplier of the Year award, coupled with aggressive cost management and our strong balance sheet position us well to continue to deliver over the long term,” continued Eyler.

 

2020 Second Quarter Financial Review

Product revenues for the second quarter of 2020 of $136.1 million declined $107.3 million, or 44.1%, as compared to the prior-year period. Excluding the impact of foreign currency translation and divested assets, product revenues declined 42.3% year over year.

 

Automotive revenues declined 45.8% year over year. All product categories saw revenue declines except Electronics. Adjusting for foreign currency translation, organic Automotive revenues decreased 44.9% year over year.  According to IHS Markit, actual light vehicle production declined by approximately 38.9% when compared to the second quarter of 2019 in the Company’s key markets of North America, Europe, China, Japan and Korea.

 


 

The 14.3% revenue decrease in Industrial resulted from the divestiture of Global Power Technologies (“GPT”), which was sold on October 1, 2019. The decrease was partially offset by year-over-year growth of 18.2% in Gentherm Medical, primarily due to increased demand for our Blanketrol® solutions, including the support of temperature management for COVID-19 patients.

See the “Revenue by Product Category” table included below for additional detail.

The gross margin rate decreased to 19.6% in the current-year period, compared with 29.9% in the prior-year period, primarily as a result of lower Automotive volume due to the COVID-19 pandemic and annual customer price reductions. These were partially offset by supplier cost reductions and positive sales mix as a result of the strength in our Medical business.

Net research and development (R&D) expenses of $15.3 million in the 2020 second quarter decreased $3.9 million, or 20.3%, year over year as a direct result of cost reduction initiatives and lower incentive compensation.

Selling, general and administrative (SG&A) expenses of $21.9 million in the 2020 second quarter decreased $10.3 million, or 32.0%, versus the prior-year period. The year-over-year decline was primarily driven by the impact of cost reduction initiatives, lower incentive compensation and the divestiture of the GPT business.

During the quarter, the Company reduced its restructuring expenses by a net $0.6 million, primarily as a result of proactively reducing cash restructuring costs associated with previously announced plan to improve the Company’s manufacturing productivity and rationalize its footprint.

As described more fully in the table included below, “Reconciliation of Net (Loss) Income to Adjusted EBITDA,” the Company recorded Adjusted EBITDA of $0.1 million during the second quarter of 2020 compared to $32.2 million in the prior year.

Income tax expense in the 2020 second quarter was $0.2 million, as compared with $5.5 million in the prior-year period. The tax amount in 2020 included the effect of the settlement and closure of multi-year international tax audits of $3.4 million. Adjusted for the audit settlement impacts, the effective tax rate was 31.4%. This rate differed from the Federal statutory rate of 21%, primarily due to higher tax rates in foreign tax jurisdictions.

GAAP diluted loss per share for the second quarter of 2020 was $0.32 compared with diluted earnings per share of $0.08 for the prior-year period. Adjusted diluted loss per share, excluding restructuring expenses, income from sale of patents, unrealized currency gain, and other impacts (see table herein), was $0.30. Adjusted diluted earnings per share in the prior-year period was $0.47.

As a result of the unprecedented uncertainty facing the automotive industry and global economy, Gentherm withdrew its 2020 guidance on March 25, 2020 and is not providing an update at this time. However, the Company expects product revenues in the third quarter of 2020 to improve sequentially to be in the range of $210 to $240 million.

Conference Call

 

As previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-855-327-6837 (callers in the U.S.) or +1-631-891-4304 (callers outside this U.S.). The passcode for the live call is 10010358.

 

 


 

A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

 

A telephonic replay will be available approximately 2 hours after the call until 11:59 pm Eastern Time on August 18, 2020. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 10010358.

 

 

Investor Relations Contact
Yijing Brentano

investors@gentherm.com
(248) 308-1702

 

Media Contact

Melissa Fischer

media@gentherm.com

248.289.9702

 

 

About Gentherm

Gentherm (NASDAQ:THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 11,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, North Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.

 

Forward-Looking Statements

 

Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this release are made as of the date hereof or as of the date specified herein and are based on management's reasonable expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause actual results or performance to differ materially from that described in or indicated by the forward-looking statements, including that: COVID-19 and its direct and indirect adverse impacts on the automobile and medical industries and global economy has, and will continue to have, an adverse effect on, among other things, the Company’s results of operations, financial condition, cash flows, liquidity, business operations and stock price; future borrowing availability under the Company’s revolving credit facility is subject to compliance with covenants thereunder, and the deterioration of the Company’s financial performance (including consolidated EBITDA) due to the COVID-19 has caused the

 


 

borrowing availability to be, and it may continue to be for at least the next 12 months, substantially less than the full amount of revolving credit facility; the Company’s failure to be in compliance with covenants under the revolving credit facility due to COVID-19 or otherwise could result in an event of default thereunder, and if the lenders thereunder do not agree to amend or waive, the amounts outstanding under the revolving credit facility may be accelerated and may become immediately due and payable; additional financing by accessing the capital markets may not be available on acceptable terms, if at all, due to the impact of COVID-19 and additional indebtedness may harm the Company’s financial position and impact the Company’s ability to comply with covenants under the Company’s revolving credit facility; the Company may not realize the expected benefits from any restructuring initiatives it may pursue as a result of the effects of COVID-19 or otherwise; declines in automobile production may have an adverse impact; sales may not increase and the projected future sales volumes on which the Company manages its business may be inaccurate; new business awards may not be converted into product revenues and our projections thereof are not updated after the date initially communicated to us by customers, including for the impact of COVID-19 on future business; new or improved competing products may be developed by competitors with greater resources; customer preferences may shift, including due to the evolving use of automobiles and technology; the Company may lose suppliers or customers; market acceptance of the Company’s existing or new products may decrease; currency exchange rates may change unfavorably; pricing pressures from customers may increase; the macroeconomic environment may present adverse conditions; new products may not be feasible; work stoppages impacting the Company, its suppliers or customers, due to labor matters, civil or political unrest, infectious diseases and epidemics or other reasons, could harm the Company’s operations; free trade agreements may be altered or additional tariffs may be implemented; customers may not accept pass-through of tariff costs; the Company may be unable to protect its intellectual property in certain jurisdictions; there may be manufacturing or design defects or other quality issues with the Company’s products; the Company may be unable to effectively implement ongoing restructuring and other cost-savings measures or realize the full amount of estimated savings; the Company’s business may be harmed by security breaches and other disruptions to its IT systems; the Company may be unable to comply with or may incur increased costs associated with complying with domestic and international regulations, which could change in an unfavorable manner; and other adverse conditions in the industries in which the Company operates may negatively affect its results.

 

The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent SEC filings, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this release does not include the potential impact of any business combinations,  acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s business and financial results.

 

Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 


 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF (LOSS) INCOME

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Product revenues

 

$

136,061

 

 

$

243,326

 

 

$

364,674

 

 

$

501,247

 

Cost of sales

 

 

109,326

 

 

 

170,612

 

 

 

271,872

 

 

 

353,226

 

Gross margin

 

 

26,735

 

 

 

72,714

 

 

 

92,802

 

 

 

148,021

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net research and development expenses

 

 

15,341

 

 

 

19,255

 

 

 

33,101

 

 

 

38,152

 

Selling, general and administrative expenses

 

 

21,889

 

 

 

32,171

 

 

 

47,729

 

 

 

64,822

 

Restructuring expenses

 

 

(598

)

 

 

1,231

 

 

 

3,168

 

 

 

3,145

 

Total operating expenses

 

 

36,632

 

 

 

52,657

 

 

 

83,998

 

 

 

106,119

 

Operating (loss) income

 

 

(9,897

)

 

 

20,057

 

 

 

8,804

 

 

 

41,902

 

Interest expense, net

 

 

(1,361

)

 

 

(1,240

)

 

 

(2,109

)

 

 

(2,608

)

Foreign currency loss

 

 

(1,741

)

 

 

(804

)

 

 

(2,679

)

 

 

(601

)

Gain on sale of business

 

 

 

 

 

 

 

 

 

 

 

4,970

 

Impairment loss

 

 

 

 

 

(9,885

)

 

 

 

 

 

(20,369

)

Other income

 

 

2,882

 

 

 

171

 

 

 

3,146

 

 

 

314

 

(Loss) earnings before income tax

 

 

(10,117

)

 

 

8,299

 

 

 

7,162

 

 

 

23,608

 

Income tax expense

 

 

205

 

 

 

5,548

 

 

 

5,611

 

 

 

12,443

 

Net (loss) income

 

$

(10,322

)

 

$

2,751

 

 

$

1,551

 

 

$

11,165

 

Basic (loss) earnings per share

 

$

(0.32

)

 

$

0.08

 

 

$

0.05

 

 

$

0.33

 

Diluted (loss) earnings per share

 

$

(0.32

)

 

$

0.08

 

 

$

0.05

 

 

$

0.33

 

Weighted average number of shares – basic

 

 

32,580

 

 

 

33,441

 

 

 

32,635

 

 

 

33,508

 

Weighted average number of shares – diluted

 

 

32,580

 

 

 

33,574

 

 

 

32,869

 

 

 

33,651

 

 


 

GENTHERM INCORPORATED

REVENUE BY PRODUCT CATEGORY

(Unaudited, in thousands)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2020

 

 

2019

 

 

% Change

 

 

2020

 

 

2019

 

 

% Change

 

Climate Control Seats (CCS)

 

$

49,879

 

 

$

88,437

 

 

 

(43.6

)%

 

$

132,407

 

 

$

182,791

 

 

 

(27.6

)%

Seat Heaters

 

 

33,342

 

 

 

73,628

 

 

 

(54.7

)%

 

 

97,874

 

 

 

147,548

 

 

 

(33.7

)%

Electronics

 

 

13,488

 

 

 

11,454

 

 

 

17.8

%

 

 

23,864

 

 

 

24,306

 

 

 

(1.8

)%

Automotive Cables

 

 

9,833

 

 

 

22,205

 

 

 

(55.7

)%

 

 

31,973

 

 

 

45,955

 

 

 

(30.4

)%

Steering Wheel Heaters

 

 

7,980

 

 

 

16,029

 

 

 

(50.2

)%

 

 

27,215

 

 

 

32,999

 

 

 

(17.5

)%

Battery Thermal Management (BTM)

 

 

6,653

 

 

 

8,897

 

 

 

(25.2

)%

 

 

17,862

 

 

 

19,641

 

 

 

(9.1

)%

Other Automotive

 

 

3,211

 

 

 

9,050

 

 

 

(64.5

)%

 

 

9,663

 

 

 

18,817

 

 

 

(48.6

)%

Subtotal Automotive

 

 

124,386

 

 

 

229,700

 

 

 

(45.8

)%

 

 

340,858

 

 

 

472,057

 

 

 

(27.8

)%

Medical

 

 

11,675

 

 

 

9,881

 

 

 

18.2

%

 

 

23,816

 

 

 

18,068

 

 

 

31.8

%

GPT

 

 

 

 

 

3,745

 

 

 

(100.0

)%

 

 

 

 

 

7,704

 

 

 

(100.0

)%

CSZ-IC

 

 

 

 

 

 

 

 

0.0

%

 

 

 

 

 

3,418

 

 

 

(100.0

)%

Subtotal Industrial

 

 

11,675

 

 

 

13,626

 

 

 

(14.3

)%

 

 

23,816

 

 

 

29,190

 

 

 

(18.4

)%

Total Company

 

 

136,061

 

 

 

243,326

 

 

 

(44.1

)%

 

 

364,674

 

 

 

501,247

 

 

 

(27.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Core Businesses (Automotive and Medical)

 

$

136,061

 

 

$

239,581

 

 

 

(43.2

)%

 

$

364,674

 

 

$

490,125

 

 

 

(25.6

)%

 


 

GENTHERM INCORPORATED

RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED EBITDA

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net (loss) income

 

$

(10,322

)

 

$

2,751

 

 

$

1,551

 

 

$

11,165

 

Add back:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

205

 

 

 

5,548

 

 

 

5,611

 

 

 

12,443

 

Interest expense

 

 

1,361

 

 

 

1,240

 

 

 

2,109

 

 

 

2,608

 

Depreciation and amortization

 

 

9,847

 

 

 

11,094

 

 

 

20,000

 

 

 

22,074

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring expense

 

 

(598

)

 

 

1,231

 

 

 

3,168

 

 

 

3,145

 

Impairment loss

 

 

 

 

 

9,885

 

 

 

 

 

 

20,369

 

Gain on sale of business

 

 

 

 

 

 

 

 

 

 

 

(4,970

)

Acquisition transaction expense

 

 

 

 

 

342

 

 

 

 

 

 

380

 

Unrealized currency loss (gain)

 

 

1,609

 

 

 

71

 

 

 

2,374

 

 

 

(923

)

Gain on sale of patents

 

 

(1,978

)

 

 

 

 

 

(1,978

)

 

 

 

CFO transition expenses

 

 

 

 

 

 

 

 

 

 

 

1,065

 

Adjusted EBITDA

 

$

124

 

 

$

32,162

 

 

$

32,835

 

 

$

67,356

 

 

Use of Non-GAAP Financial Measures

 

In addition to the results reported in accordance with GAAP throughout this release, the Company has provided information regarding adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) and adjusted earnings per share (“Adjusted earnings per share” or “Adjusted EPS”), each, a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Adjusted EPS as earnings adjusted by gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company’s reconciliation of net income to Adjusted EBITDA is provided in this release. The Company’s Reconciliation of Adjusted EPS can be found in the supplemental materials furnished as Exhibit 99.2 to the Company’s Form 8-K dated August 4, 2020 and also is included in the presentation entitled “Q2 2020 Gentherm Incorporated Earnings Conference Presentation,” which can be found on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

 

In evaluating its business, the Company considers and uses Adjusted EBITDA and Adjusted EPS as supplemental measures of its operating performance. Management provides Adjusted EBITDA and Adjusted EPS measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis. Other companies in our industry may calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA or Adjusted EPS in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP.

 

Non-GAAP measures referenced in this release may include estimates of future Adjusted EBITDA and Adjusted EPS. Such forward-looking non-GAAP measures may differ significantly from the corresponding GAAP measures, due to depreciation and amortization, tax expense, and/or interest expense, some or all of which management has not quantified for the future periods.

 


 

GENTHERM INCORPORATED

ACQUISITION TRANSACTION EXPENSES, PURCHASE ACCOUNTING IMPACTS

AND OTHER EFFECTS

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

 

June 30,

 

 

June 30,

 

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

 

Transaction related current expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition transaction expenses

 

$

 

 

$

342

 

 

$

 

 

$

380

 

 

Non-cash purchase accounting impacts

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer relationships amortization

 

 

1,595

 

 

 

1,936

 

 

 

3,191

 

 

 

3,764

 

 

Technology amortization

 

 

438

 

 

 

498

 

 

 

877

 

 

 

980

 

 

Inventory fair value adjustment

 

 

108

 

 

 

117

 

 

 

216

 

 

 

156

 

 

Other effects

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring expenses

 

 

(598

)

 

 

1,231

 

 

 

3,168

 

 

 

3,145

 

 

Gain on sale of business

 

 

 

 

 

 

 

 

 

 

 

(4,970

)

 

Gain on sale of patents

 

 

(1,978

)

 

 

 

 

 

(1,978

)

 

 

 

 

Impairment loss

 

 

 

 

 

9,885

 

 

 

 

 

 

20,369

 

 

Unrealized currency (gain) loss

 

 

1,609

 

 

 

71

 

 

 

2,374

 

 

 

(923

)

 

CFO transition

 

 

 

 

 

 

 

 

 

 

 

1,065

 

 

Total acquisition transaction expenses, purchase accounting

     impacts and other effects

 

$

1,174

 

 

$

14,080

 

 

$

7,848

 

 

$

23,966

 

 

Tax effect of above

 

 

(619

)

 

 

(1,117

)

 

 

(2,329

)

 

 

(905

)

 

Net income effect

 

$

555

 

 

$

12,963

 

 

$

5,519

 

 

$

23,061

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share - difference

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.02

 

 

$

0.39

 

 

$

0.17

 

 

$

0.69

 

 

Diluted

 

$

0.02

 

 

$

0.39

 

 

$

0.17

 

 

$

0.69

 

 

Adjusted earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.30

)

 

$

0.47

 

 

$

0.22

 

 

$

1.02

 

 

Diluted

 

$

(0.30

)

 

$

0.47

 

 

$

0.22

 

 

$

1.02

 

 

 


 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

 

 

 

June 30, 2020

 

 

December 31, 2019

 

ASSETS

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

209,170

 

 

$

50,443

 

Restricted cash

 

 

2,505

 

 

 

2,505

 

Accounts receivable, less allowance of $1,800 and $1,193, respectively

 

 

118,885

 

 

 

159,710

 

Inventory:

 

 

 

 

 

 

 

 

Raw materials

 

 

61,762

 

 

 

61,323

 

Work in process

 

 

6,575

 

 

 

7,444

 

Finished goods

 

 

44,293

 

 

 

49,712

 

Inventory, net

 

 

112,630

 

 

 

118,479

 

Other current assets

 

 

36,592

 

 

 

42,726

 

Total current assets

 

 

479,782

 

 

 

373,863

 

Property and equipment, net

 

 

149,240

 

 

 

160,605

 

Goodwill

 

 

64,629

 

 

 

64,572

 

Other intangible assets, net

 

 

48,399

 

 

 

49,783

 

Operating lease right-of-use assets

 

 

12,780

 

 

 

11,587

 

Deferred income tax assets

 

 

57,972

 

 

 

57,650

 

Other non-current assets

 

 

10,568

 

 

 

9,326

 

Total assets

 

$

823,370

 

 

$

727,386

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

65,521

 

 

$

83,035

 

Current lease liabilities

 

 

4,184

 

 

 

4,586

 

Current maturities of long-term debt

 

 

2,500

 

 

 

2,500

 

Other current liabilities

 

 

63,805

 

 

 

66,583

 

Total current liabilities

 

 

136,010

 

 

 

156,704

 

Long-term debt, less current maturities

 

 

198,099

 

 

 

78,124

 

Pension benefit obligation

 

 

7,690

 

 

 

8,057

 

Non-current lease liabilities

 

 

10,097

 

 

 

6,751

 

Other non-current liabilities

 

 

2,153

 

 

 

5,100

 

Total liabilities

 

$

354,049

 

 

$

254,736

 

Shareholders’ equity:

 

 

 

 

 

 

 

 

Common Stock:

 

 

 

 

 

 

 

 

No par value; 55,000,000 shares authorized 32,639,752 and 32,674,354 issued and outstanding at June 30, 2020 and December 31, 2019, respectively

 

 

104,113

 

 

 

102,507

 

Paid-in capital

 

 

9,770

 

 

 

10,852

 

Accumulated other comprehensive loss

 

 

(47,845

)

 

 

(42,441

)

Accumulated earnings

 

 

403,283

 

 

 

401,732

 

Total shareholders’ equity

 

 

469,321

 

 

 

472,650

 

Total liabilities and shareholders’ equity

 

$

823,370

 

 

$

727,386

 

 


 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Six Months Ended June 30,

 

 

 

2020

 

 

2019

 

Operating Activities:

 

 

 

 

 

 

 

 

Net income

 

$

1,551

 

 

$

11,165

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

20,488

 

 

 

22,217

 

Deferred income taxes

 

 

(913

)

 

 

3,070

 

Stock based compensation

 

 

3,909

 

 

 

3,291

 

Defined benefit plan income

 

 

(278

)

 

 

(699

)

Allowance for credit losses

 

 

605

 

 

 

545

 

Loss on sale of property and equipment

 

 

339

 

 

 

227

 

Operating lease expense

 

 

3,490

 

 

 

2,903

 

Impairment loss

 

 

 

 

 

20,369

 

Gain on sale of business

 

 

 

 

 

(4,970

)

Gain on sale of patents

 

 

(1,978

)

 

 

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

37,805

 

 

 

(4,021

)

Inventory

 

 

5,292

 

 

 

1,650

 

Other assets

 

 

2,888

 

 

 

276

 

Accounts payable

 

 

(17,753

)

 

 

(9,528

)

Other liabilities

 

 

(5,218

)

 

 

(6,087

)

Net cash provided by operating activities

 

 

50,227

 

 

 

40,408

 

Investing Activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(7,500

)

 

 

(13,024

)

Acquisition of intangible assets

 

 

(3,141

)

 

 

 

Proceeds from the sale of patents and property and equipment

 

 

1,061

 

 

 

82

 

Proceeds from divestiture of business

 

 

 

 

 

47,500

 

Acquisition of subsidiary, net of cash acquired

 

 

 

 

 

(15,476

)

Net cash (used in) provided by investing activities

 

 

(9,580

)

 

 

19,082

 

Financing Activities:

 

 

 

 

 

 

 

 

Borrowing of debt

 

 

201,193

 

 

 

28,371

 

Repayments of debt

 

 

(81,830

)

 

 

(61,120

)

Cash paid for financing costs

 

 

 

 

 

(1,278

)

Cash paid for the cancellation of restricted stock

 

 

(471

)

 

 

(926

)

Proceeds from the exercise of Common Stock options

 

 

6,178

 

 

 

4,771

 

Cash paid for the repurchase of Common Stock

 

 

(9,092

)

 

 

(33,040

)

Net cash provided by (used in) financing activities

 

 

115,978

 

 

 

(63,222

)

Foreign currency effect

 

 

2,102

 

 

 

293

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

158,727

 

 

 

(3,439

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

52,948

 

 

 

39,620

 

Cash, cash equivalents and restricted cash at end of period

 

$

211,675

 

 

$

36,181

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Cash (refund) paid for taxes

 

$

(3,117

)

 

$

3,522

 

Cash paid for interest

 

$

1,967

 

 

$

2,712

 

 

 

 

# # # #

 

 

thrm-ex992_71.pptx.htm

Slide 1

2020 Second Quarter Results Gentherm, Inc. August 4, 2020 Exhibit 99.2

Slide 2

Forward-Looking Statement Except for historical information contained herein, statements in this presentation are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this presentation are made as of the date hereof or as of the date specified herein and are based on management's reasonable expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause actual results or performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that: COVID-19 and its direct and indirect adverse impacts on the automobile and medical industries and the global economy has, and will continue to have, an adverse effect on, among other things, the Company’s results of operations, financial condition, cash flows, liquidity, business operations and stock price; future borrowing availability under the revolving credit facility is subject to compliance with covenants, and to the extent that the Company’s financial performance (including consolidated EBITDA) deteriorates due to COVID-19 impacts or otherwise, the Company’s borrowing availability may be substantially less than the full amount of the facility; the Company’s failure to be in compliance with covenants under the revolving credit facility due to COVID-19 or otherwise could result in an event of default thereunder, and if the lenders do not agree to amend or waive, the amounts outstanding may be accelerated and become immediately due and payable; additional financing by accessing the capital markets may not be available on acceptable terms, if at all, due to the impact of COVID-19 and additional indebtedness may harm the Company’s financial position and impact the Company’s ability to comply with covenants under the revolving credit facility; the Company may not realize the expected benefits from any restructuring initiatives it may pursue as a result of the effects of COVID-19; declines in automobile production may have an adverse impact; sales may not increase and the projected future sales volumes on which the Company manages its business may be inaccurate; new business awards may not be converted into product revenues and our projections thereof are not updated after the date initially communicated to us by customers, including for the impact of COVID-19 on future business; new or improved competing products may be developed by competitors with greater resources; customer preferences may shift, including due to the evolving use of automobiles and technology; the Company may lose suppliers or customers; market acceptance of the Company’s existing or new products may decrease; currency exchange rates may change unfavorably; pricing pressures from customers may increase; the macroeconomic environment may present adverse conditions; new products may not be feasible; work stoppages impacting the Company, its suppliers or customers, due to labor matters, civil or political unrest, infectious diseases and epidemics or other reasons, could harm the Company’s operations; free trade agreements may be altered or additional tariffs may be implemented; customers may not accept pass-through of tariff costs; the Company may be unable to protect its intellectual property in certain jurisdictions; there may be manufacturing or design defects or other quality issues with the Company’s products; the Company may be unable to effectively implement ongoing restructuring and other cost-savings measures or realize the full amount of estimated savings; the Company’s business may be harmed by security breaches and other disruptions to its IT systems; the Company may be unable to comply with or may incur increased costs associated with complying with domestic and international regulations, which could change in an unfavorable manner; and other adverse conditions in the industries in which the Company operates may negatively affect its results. The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors,” in its most recent Annual Report on Form 10-K and subsequent SEC filings, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this release does not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s business and financial results. Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Slide 3

Use of Non-GAAP Financial Measures* In addition to the results reported in accordance with GAAP throughout this presentation, the Company has provided information regarding Adjusted EBITDA and Adjusted EPS, each a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings (loss) before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses that the Company believes are not reflective of its ongoing operations and related tax effects including transaction expenses, CFO transition expenses, impairment of assets held for sale, gain or loss on sale of business, gain on sale of patents, restructuring expenses and unrealized currency gain or loss. The Company defines Adjusted EPS as earnings (loss) per share on a diluted basis, adjusted by gains and losses that the Company believes are not reflective of its ongoing operations and related tax effects including transaction expenses, non-cash purchase accounting impacts, impairment of assets held for sale, gain or loss on sale of business, restructuring expenses, gain on sale of patents, unrealized currency gain or loss, and CFO transition expenses. In evaluating its business, the Company considers and uses Adjusted EBITDA and Adjusted EPS as supplemental measures of its operating performance. Management provides these non-GAAP measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance and liquidity, respectively, on a period-over-period basis. Other companies in our industry may calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance and liquidity, respectively, investors should not consider these non-GAAP measures in isolation, or as a substitute for net income (loss), earnings (loss) per share or other consolidated income statement data prepared in accordance with GAAP.  * See Appendix for certain reconciliations of GAAP to non-GAAP historical financial measures

Slide 4

2Q 2020 Highlights Strong execution despite challenging conditions Continued to outperform in each of the key automotive markets $300M in Automotive new business awards Drove double digit revenue growth in Medical - both year over year and sequentially Reduced operating expense by 30% year over year Generated a 24% increase in cash flow from operations in the first half Strong balance sheet with total liquidity of $369 million at quarter end

Slide 5

Automotive 2Q 2020 Highlights Continued momentum in Automotive Recognized by General Motors as a 2019 Supplier of the Year Winner 30 Vehicle launches with 29 OEMs Multiple CCS® product launches Acura MDX Chevrolet Bolt / Blazer Chevrolet Silverado GMC Sierra Hongqi HS7 KIA K5 / Optima Launched phase two advanced ClimateSense™ development project with BMW Lear and Gentherm introduced INTU™ Thermal Comfort Seating with ClimateSense™ technology

Slide 6

Automotive Awards Record win rate for new business awards $300M in awards in 2Q across 11 OEMs Over 90% win rate in the quarter Multiple CCS® awards BMWCadillac FordGM BEV Platform Hyundai Steering heater awards across 5 OEMs Expanded business with Toyota with seat heater awards for Lexus RX / NX and Toyota Sequoia

Slide 7

Medical 2Q 2020 Highlights Continued strong growth in the Medical business Record quarterly revenue; up 18% year over year Continued revenue growth in Blanketrol® equipment globally to support temperature management of COVID-19 patients Hemotherm® now able to be utilized for extracorporeal membrane oxygenation (ECMO) therapy under FDA Emergency Use Authorization for COVID-19 patients

Slide 8

Summary Positioned well to continue to deliver over the long term Executed against strategic plan Focused growth Divested non-core businesses Realigned cost structure Bringing innovative solutions to market Remain highly focused on strong execution Capabilities to pivot resources to meet immediate customer needs Strong balance sheet and financial resources

Slide 9

Selected Income Statement Data 2020 2019 2020 2019 Product Revenues $ 136,061 $ 243,326 $ 364,674 $ 501,247 Gross Margin 26,735 72,714 92,802 148,021 Gross Margin % 19.6% 29.9% 25.4% 29.5% Operating Expenses 36,632 52,657 83,998 106,119 Operating (Loss) Income (9,897) 20,057 8,804 41,902 Adjusted EBITDA 124 32,162 32,835 67,356 Diluted EPS - As Adjusted (0.30) 0.47 0.22 1.02 Three Months Ended June 30, Six Months Ended June 30, (Dollars in thousands, except per share data)

Slide 10

Selected Balance Sheet Data   June 30, 2020 December 31, 2019 Cash and Cash Equivalents $ 209,170 $ 50,443 Restricted Cash 2,505 2,505 Total Assets 823,370 727,386 Debt 200,599 80,624 Current 2,500 2,500 Non-Current 198,099 78,124 Revolving LOC Availability 159,342 392,325 Total Liquidity 368,512 442,768 (Dollars in thousands)

Slide 11

Appendix

Slide 12

Reconciliation of Net (Loss) Income to Adjusted EBITDA   2020 2019 2020 2019 Net (Loss) Income $ (10,322) $ 2,751 $ 1,551 $ 11,165 Add Back:     Income Tax Expense 205 5,548 5,611 12,443 Interest Expense 1,361 1,240 2,109 2,608 Depreciation and Amortization 9,847 11,094 20,000 22,074 Adjustments: Restructuring Expenses (598) 1,231 3,168 3,145 Impairment Loss — 9,885 — 20,369 Gain on Sale of Business — — — (4,970) Acquisition Transaction Expense — 342 — 380 Unrealized Currency Loss (Gain) 1,609 71 2,374 (923) Gain on Sale of Patents (1,978) — (1,978) — CFO Transition Expense — — — 1,065 Adjusted EBITDA $ 124 $ 32,162 $ 32,835 $ 67,356 Three Months Ended June 30, Six Months Ended June 30,

Slide 13

Reconciliation of Adjusted EPS   2020 2019 2020 2019 Diluted EPS - As Reported $ (0.32) $ 0.08 $ 0.05 $ 0.33 Acquisition Transaction Expenses — 0.01 — 0.01 Non-Cash Purchase Accounting Impacts 0.07 0.08 0.13 0.15 Unrealized Currency Loss (Gain) 0.05 — 0.07 (0.02) Restructuring Expenses (0.02) 0.04 0.10 0.09 Gain on Sale of Patents (0.06) — (0.06) — Impairment Loss and Gain on Sale of Business — 0.29 — 0.46 CFO Transition Expenses — — — 0.03 Tax Effect of Above (0.02) (0.03) (0.07) (0.03) Diluted EPS - As Adjusted $ (0.30) $ 0.47 $ 0.22 $ 1.02 Three Months Ended June 30, Six Months Ended June 30,

Slide 14

v3.20.2
Document and Entity Information
Aug. 04, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 04, 2020
Entity Registrant Name GENTHERM Inc
Entity Central Index Key 0000903129
Entity Emerging Growth Company false
Entity File Number 0-21810
Entity Incorporation State Country Code MI
Entity Tax Identification Number 95-4318554
Entity Address, Address Line One 21680 Haggerty Road
Entity Address, City or Town Northville
Entity Address, State or Province MI
Entity Address, Postal Zip Code 48167
City Area Code (248)
Local Phone Number 504-0500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, no par value
Trading Symbol THRM
Security Exchange Name NASDAQ